Fortis Capital Advisors »

Galectin Therapeutics shares owned by Fortis Capital Advisors

Quarter-by-quarter ownership of Galectin Therapeutics (GALT) shares owned by Fortis Capital Advisors from 13F filings

Historical chart of Fortis Capital Advisors investment in Galectin Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Galectin Therapeutics held by Fortis Capital Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Galectin Therapeutics by Fortis Capital Advisors

Quarter filed Position value Share count Share price at filing
2025-12-31 $442k 106k 4.16

More positions owned by Fortis Capital Advisors

NVIDIA Corporation (NVDA)
Schwab Strategic Tr Etf (SCHX)
Invesco Qqq Tr Etf (QQQ)
Sch Fnd Us Lg Etf schwb fdt us lg (FNDX)
Schwab Strategic Tr Etf (SCHG)
SPDR S&P 500 Etf (SPY)
Schwab Strategic Tr Etf (SCHF)
Apple (AAPL)
Microsoft Corporation (MSFT)
Spdr Series Trust Etf (BIL)
Ishares Tr Etf (IVV)
Ishares Tr Etf (IJR)
Vanguard Index Fds Etf (VO)
Amazon (AMZN)
Palantir Technologies (PLTR)

View all positions for Fortis Capital Advisors

Top funds holding Galectin Therapeutics

Vanguard Group
Advisor Group Holdings
Susquehanna International
BlackRock
Marshall Wace
Sontag Advisory
Geode Capital Management
Jane Street
Commonwealth Equity Services
LPL Financial
Goldman Sachs Group
Geneos Wealth Management
State Street Corporation
Sovran Advisors
Vivaldi Capital Management

View all funds holding Galectin Therapeutics